Cassava Sciences Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Cassava Sciences wird ein Gewinn- und Umsatzwachstum von 17.5% bzw. 32.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 23.3% pro Jahr wachsen soll.
Wichtige Informationen
17.5%
Wachstumsrate der Gewinne
23.3%
EPS-Wachstumsrate
Pharmaceuticals Gewinnwachstum | 27.6% |
Wachstumsrate der Einnahmen | 32.6% |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Low |
Zuletzt aktualisiert | 17 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 26Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | N/A | -67 | N/A | N/A | 1 |
12/31/2025 | 100 | 18 | N/A | N/A | 2 |
12/31/2024 | N/A | -37 | N/A | N/A | 2 |
3/31/2024 | N/A | -48 | -88 | -88 | N/A |
12/31/2023 | N/A | -97 | -82 | -82 | N/A |
9/30/2023 | N/A | -95 | -81 | -81 | N/A |
6/30/2023 | N/A | -90 | -77 | -76 | N/A |
3/31/2023 | N/A | -83 | -70 | -67 | N/A |
12/31/2022 | N/A | -76 | -80 | -78 | N/A |
9/30/2022 | N/A | -71 | -67 | -64 | N/A |
6/30/2022 | N/A | -61 | -81 | -57 | N/A |
3/31/2022 | N/A | -46 | -74 | -51 | N/A |
12/31/2021 | N/A | -32 | -52 | -30 | N/A |
9/30/2021 | N/A | -21 | -45 | -23 | N/A |
6/30/2021 | N/A | -13 | -11 | -11 | N/A |
3/31/2021 | N/A | -9 | -6 | -6 | N/A |
12/31/2020 | N/A | -6 | -5 | -5 | N/A |
9/30/2020 | N/A | -5 | -5 | -5 | N/A |
6/30/2020 | N/A | -4 | -3 | -3 | N/A |
3/31/2020 | N/A | -4 | -3 | -3 | N/A |
12/31/2019 | N/A | -5 | -3 | -3 | N/A |
9/30/2019 | N/A | -4 | -3 | -2 | N/A |
6/30/2019 | N/A | -4 | -3 | -3 | N/A |
3/31/2019 | N/A | -6 | -4 | -4 | N/A |
12/31/2018 | N/A | -7 | -5 | -5 | N/A |
9/30/2018 | N/A | -8 | -6 | -6 | N/A |
6/30/2018 | N/A | -10 | -6 | -6 | N/A |
3/31/2018 | N/A | -11 | -8 | -8 | N/A |
12/31/2017 | N/A | -12 | N/A | -8 | N/A |
9/30/2017 | N/A | -12 | N/A | -10 | N/A |
6/30/2017 | N/A | -13 | N/A | -10 | N/A |
3/31/2017 | N/A | -12 | N/A | -11 | N/A |
12/31/2016 | N/A | -15 | N/A | -12 | N/A |
9/30/2016 | N/A | -17 | N/A | -13 | N/A |
6/30/2016 | N/A | -17 | N/A | -12 | N/A |
3/31/2016 | N/A | -17 | N/A | -11 | N/A |
12/31/2015 | N/A | -14 | N/A | -9 | N/A |
9/30/2015 | N/A | -12 | N/A | -8 | N/A |
6/30/2015 | N/A | -12 | N/A | -7 | N/A |
3/31/2015 | N/A | -12 | N/A | -8 | N/A |
12/31/2014 | N/A | -12 | N/A | -10 | N/A |
9/30/2014 | 35 | 23 | N/A | -8 | N/A |
6/30/2014 | 37 | 26 | N/A | -9 | N/A |
3/31/2014 | 39 | 29 | N/A | -8 | N/A |
12/31/2013 | 41 | 32 | N/A | -7 | N/A |
9/30/2013 | 8 | -3 | N/A | -7 | N/A |
6/30/2013 | 9 | -4 | N/A | -7 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: SAVA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: SAVA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: SAVA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: SAVADie Einnahmen des Unternehmens (32.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: SAVADie Einnahmen des Unternehmens (32.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SAVA in 3 Jahren voraussichtlich hoch sein wird